141 related articles for article (PubMed ID: 29948962)
21. Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients.
Smolen JS; van Vollenhoven R; Kavanaugh A; Strand V; Vencovsky J; Schiff M; Landewé R; Haraoui B; Arendt C; Mountian I; Carter D; van der Heijde D
Arthritis Res Ther; 2015 Sep; 17(1):245. PubMed ID: 26353833
[TBL] [Abstract][Full Text] [Related]
22. The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression.
Atsumi T; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Yasuda S; Yamanishi Y; Kita Y; Matsubara T; Iwamoto M; Shoji T; Okada T; van der Heijde D; Miyasaka N; Koike T
Ann Rheum Dis; 2016 Jan; 75(1):75-83. PubMed ID: 26139005
[TBL] [Abstract][Full Text] [Related]
23. [Safety and effectiveness of certolizumab pegol in patients with rheumatoid arthritis: Interim analysis of post-marketing surveillance].
Kameda H; Nishida K; Nannki T; Watanabe A; Oshima Y; Momohara S
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(3):196-205. PubMed ID: 28747607
[TBL] [Abstract][Full Text] [Related]
24. Pregnancy Outcomes in Subjects Exposed to Certolizumab Pegol.
Clowse ME; Wolf DC; Förger F; Cush JJ; Golembesky A; Shaughnessy L; De Cuyper D; Mahadevan U
J Rheumatol; 2015 Dec; 42(12):2270-8. PubMed ID: 26523031
[TBL] [Abstract][Full Text] [Related]
25. Possible relationship between certolizumab pegol and arrhythmias: report of two cases.
Talotta R; Atzeni F; Batticciotto A; Ventura D; Sarzi-Puttini P
Reumatismo; 2016 Sep; 68(2):104-8. PubMed ID: 27608800
[TBL] [Abstract][Full Text] [Related]
26. Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population.
Weinblatt ME; Fleischmann R; van Vollenhoven RF; Emery P; Huizinga TW; Cutolo M; van der Heijde D; Duncan B; Davies O; Luijtens K; Dougados M
Arthritis Res Ther; 2015 Nov; 17():325. PubMed ID: 26568428
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness and survival-on-drug of certolizumab pegol in rheumatoid arthritis in clinical practice: results from the national Swedish register.
Chatzidionysiou K; Kristensen LE; Eriksson J; Askling J; van Vollenhoven R;
Scand J Rheumatol; 2015; 44(6):431-7. PubMed ID: 26084325
[TBL] [Abstract][Full Text] [Related]
28. Matrix metalloproteinase-3 and the 7-joint ultrasound score in the assessment of disease activity and therapeutic efficacy in patients with moderate to severe rheumatoid arthritis.
Zhou L; Wang G; Liu X; Song J; Chen L; Xu H
Arthritis Res Ther; 2017 Nov; 19(1):250. PubMed ID: 29141665
[TBL] [Abstract][Full Text] [Related]
29. Modeling of the clinical and economic impact of a risk-sharing agreement supporting a treat-to-target strategy in the management of patients with rheumatoid arthritis in France.
Fagnani F; Pham T; Claudepierre P; Berenbaum F; De Chalus T; Saadoun C; Joubert JM; Fautrel B
J Med Econ; 2016 Aug; 19(8):812-21. PubMed ID: 27065315
[TBL] [Abstract][Full Text] [Related]
30. Non-infectious pulmonary complications of newer biological agents for rheumatic diseases--a systematic literature review.
Hadjinicolaou AV; Nisar MK; Bhagat S; Parfrey H; Chilvers ER; Ostör AJ
Rheumatology (Oxford); 2011 Dec; 50(12):2297-305. PubMed ID: 22019799
[TBL] [Abstract][Full Text] [Related]
31. Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activity.
Pope J; Bingham CO; Fleischmann RM; Dougados M; Massarotti EM; Wollenhaupt J; Duncan B; Coteur G; Weinblatt ME
Arthritis Res Ther; 2015 Nov; 17():343. PubMed ID: 26614481
[TBL] [Abstract][Full Text] [Related]
32. Designing an over-the-counter consumer decision-making tool for older adults.
Martin-Hammond AM; Abegaz T; Gilbert JE
J Biomed Inform; 2015 Oct; 57():113-23. PubMed ID: 26184058
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial.
Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Shoji T; Sakamaki Y; van der Heijde D; Miyasaka N; Koike T
Mod Rheumatol; 2014 Sep; 24(5):715-24. PubMed ID: 24313916
[TBL] [Abstract][Full Text] [Related]
34. Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment.
Curtis JR; Winthrop K; O'Brien C; Ndlovu MN; de Longueville M; Haraoui B
Arthritis Res Ther; 2017 Dec; 19(1):276. PubMed ID: 29246162
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: the HIKARI randomized, placebo-controlled trial.
Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Iwai K; Sakamaki Y; van der Heijde D; Miyasaka N; Koike T
Mod Rheumatol; 2014 Jul; 24(4):552-60. PubMed ID: 24981319
[TBL] [Abstract][Full Text] [Related]
36. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
Ruiz Garcia V; Jobanputra P; Burls A; Cabello JB; Gálvez Muñoz JG; Saiz Cuenca ES; Fry-Smith A
Cochrane Database Syst Rev; 2011 Feb; (2):CD007649. PubMed ID: 21328299
[TBL] [Abstract][Full Text] [Related]
37. Comparison of certolizumab pegol with other anticytokine agents for treatment of rheumatoid arthritis: a multiple-treatment Bayesian metaanalysis.
Launois R; Avouac B; Berenbaum F; Blin O; Bru I; Fautrel B; Joubert JM; Sibilia J; Combe B
J Rheumatol; 2011 May; 38(5):835-45. PubMed ID: 21239748
[TBL] [Abstract][Full Text] [Related]
38. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
[TBL] [Abstract][Full Text] [Related]
39. Use of rheumatology-specific patient navigators to understand and reduce barriers to medication adherence: Analysis of qualitative findings.
Wohlfahrt A; Campos A; Iversen MD; Gagne JJ; Massarotti E; Solomon DH; Feldman CH
PLoS One; 2018; 13(7):e0200886. PubMed ID: 30024938
[TBL] [Abstract][Full Text] [Related]
40. How the Consolidated Framework for Implementation Research Can Strengthen Findings and Improve Translation of Research Into Practice: A Case Study.
Klafke N; Mahler C; von Hagens C; Wensing M; Schneeweiss A; Müller A; Szecsenyi J; Joos S
Oncol Nurs Forum; 2017 Sep; 44(5):E223-E231. PubMed ID: 28820519
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
